Participant flow

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma · Source last updated 2019-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   ClaPd therapy: Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle. Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day. dexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle clarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle Pomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle

   id

   FG000

   title

   All Patients

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      non-evaluable/not included in analysis

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Withdrawal by Subject

   6. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      still on treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         121

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         100

      comment

      Completion defined as those that were removed from treatment due to disease progression.

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      NOT COMPLETED

   title

   Treatment Phase

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         18

      type

      still being followed for overall surviva

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         112

      comment

      Follow-up includes all patients except those that passed away on treatment or were non-evaluable.

      type

      STARTED

   2. achievements

      1. comment

         Completion defined as those that are no longer in long term follow up due to death.

         group Id

         FG000

         num Subjects

         92

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         20

      type

      NOT COMPLETED

   title

   Follow Up Phase

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice